Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 2Active not recruiting 2Unknown 1Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Carcinoma, Non-Small-Cell Lung 13Breast Neoplasms 13Pancreatic Neoplasms 10Ovarian Neoplasms 10Fallopian Tube Neoplasms 10Lung Neoplasms 8Triple Negative Breast Neoplasms 7Squamous Cell Carcinoma of Head and Neck 7Neoplasm Metastasis 4Esophageal Neoplasms 4Endometrial Neoplasms 4Oropharyngeal Neoplasms 3Mouth Neoplasms 3Melanoma 3Inflammatory Breast Neoplasms 3Hypopharyngeal Neoplasms 3Head and Neck Neoplasms 3Colorectal Neoplasms 3Carcinoma, Transitional Cell 3Carcinoma 3Stomach Neoplasms 2Pancreatic Adenocarcinoma 2Neoplasms, Squamous Cell 2Neoplasms 2Laryngeal Neoplasms 2Esophageal Squamous Cell Carcinoma 2Cholangiocarcinoma 2Carcinoma, Squamous Cell 2Brenner Tumor 2Adenocarcinoma of Lung 2

Interventions

Oxaliplatin 7Fluorouracil 7Leucovorin 6pembrolizumab 4Paclitaxel 4Capecitabine 4Radiotherapy 3Radiation 3Nivolumab 3Cisplatin 3zimberelimab 2tislelizumab 2durvalumab 2Trastuzumab 2Taxes 2Levoleucovorin 2Irinotecan 2zanidatamab 1tucatinib 1trifluridine tipiracil drug combination 1tremelimumab 1trastuzumab deruxtecan 1spartalizumab 1quemliclustat 1obinutuzumab 1naptumomab estafenatox 1lenvatinib 1futibatinib 1dehydroftorafur 1cixutumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Adenocarcinoma Of Esophagus × Taxes × Clear all
NCT01142388 2026-05-29

Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
94 enrolled 8 charts
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT04929392 2025-09-04

Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer

City of Hope Medical Center

Phase 2 Active not recruiting
3 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡